Apolipoprotein B and Cardiovascular Disease Risk: Position Statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices

Contois, John H; McConnell, Joseph P; Sethi, Amar A; Csako, Gyorgy; Devaraj, Sridevi; Hoefner, Daniel M; Warnick, G Russell

doi:10.1373/clinchem.2008.118356

Cited by 326Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and LipoproteinsCholesterol and Lipid Metabolism

Apolipoprotein B and Cardiovascular Disease Risk: Position Statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices

Open access

Contois, John H, McConnell, Joseph P, Sethi, Amar A, Csako, Gyorgy, Devaraj, Sridevi, Hoefner, Daniel M, Warnick, G Russell·2009·Clinical Chemistry

DOI 10.1373/clinchem.2008.118356

Open this paper in CoChat — free account Open PDF

Abstract

Background: Low-density lipoprotein cholesterol (LDL-C) has been the cornerstone measurement for assessing cardiovascular risk for nearly 20 years. Content: Recent data demonstrate that apolipoprotein B (apo B) is a better measure of circulating LDL particle number (LDL-P) concentration and is a more reliable indicator of risk than LDL-C, and there is growing support for the idea that addition of apo B measurement to the routine lipid panel for assessing and monitoring patients at risk for cardiovascular disease (CVD) would enhance patient management. In this report, we review the studies of apo B and LDL-P reported to date, discuss potential advantages of their measurement over that of LDL-C, and present information related to standardization. Conclusions: In line with recently adopted Canadian guidelines, the addition of apo B represents a logical next step to National Cholesterol Education Program Adult Treatment Panel III (NCEP ATPIII) and other guidelines in the US. Considering that it has taken years to educate physicians and patients regarding the use of LDL-C, changing perceptions and practices will not be easy. Thus, it appears prudent to consider using apo B along with LDL-C to assess LDL-related risk for an interim period until the superiority of apo B is generally recognized.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1373/clinchem.2008.118356

Cites

97 of 97 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Even at peak postprandial concentrations, the number of chylomicron-apoB48 particles in healthy individuals is usually < 1% and the number of VLDL-apoB100 particles is < 10% of the number of LDL-apoB100 particles.
“ApoB can be measured in the nonfasting state because even at peak postprandial concentrations, the number of chylomicron-apoB48 particles in healthy individuals is usually < 1% and the number of VLDL-apoB100 particles is < 10% of the number of LDL-apoB100 particles [12].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [12]
The MEASUREMENT ISSUES section (p. 9) says fasting is not required for apo B measurement, and the apo B-CONTAINING LIPOPROTEINS AND CVD RISK section (p. 2) says most plasma apo B is associated with LDL. Neither passage gives the claimed <1% chylomicron-apoB48 or <10% VLDL-apoB100 particle ratios at peak postprandial concentrations in healthy individuals. (LLM, conf=0.88)
Experimental — accuracy not yet measured
ApoB is the structural protein for all non-HDL lipoproteins and exists as 2 isoforms: apoB100, the major isoform in VLDL, IDL, LDL, and Lp(a), and apoB48 in chylomicrons and chylomicron remnants.
“It is the structural protein for all non-HDL lipoproteins and exists as 2 isoforms: apoB100, the major isoform in VLDL, IDL, LDL, and Lp(a), and apoB48 in chylomicrons and chylomicron remnants [12].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [12]
The ‘apo B STRUCTURE AND FUNCTION’ section (p. 2) identifies two isoforms and calls apo B-48 the structural protein of chylomicrons. The ‘apo B-CONTAINING LIPOPROTEINS AND CVD RISK’ section (p. 2) lists VLDL, IDL, LDL, and Lp(a) as apo B-containing particles. Our copy does not explicitly assign apo B-100 to each of those particles or mention apo B-48 in chylomicron remnants. (LLM, conf=0.82)
Experimental — accuracy not yet measured
apoB can be measured more accurately, more precisely, and more selectively than LDL-C or non-HDL-C.
“Taken together with the evidence that apoB can be measured more accurately, more precisely, and more selectively than LDL-C or non-HDL-C,1,29–31”
From Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention (2024) · cites this paper as [30]
The MEASUREMENT ISSUES section (pp. 9–10) says apoB measurement is more amenable to standardization than LDL-C measurement, reports between-laboratory precision for apoB assays, and identifies specificity problems with direct LDL-C assays. It does not establish that apoB is more accurate, precise, and selective than non-HDL-C, or directly compare precision with LDL-C. (LLM, conf=0.85)
Experimental — accuracy not yet measured
Measurement of apolipoprotein B (apoB) or advanced measurement of LDLP can be used to assess the number of LDL particles.
“Measurement of apolipoprotein B (apoB), the major protein component of LDL, or advanced measurement of LDLP (not yet widely available) can also be used to assess the number of LDL particles [10,12].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [12]
ApoB can be measured in the nonfasting state.
“ApoB can be measured in the nonfasting state because even at peak postprandial concentrations, the number of chylomicron-apoB48 particles in healthy individuals is usually < 1% and the number of VLDL-apoB100 particles is < 10% of the number of LDL-apoB100 particles [12].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [12]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Low-Density Lipoprotein Subclass Patterns and Risk of Myocardial Infarction
Austin, M. A. (1988) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1988.03410130125037 · Cited by 1,780 · see citing works
Newly identified loci that influence lipid concentrations and risk of coronary artery disease
Willer, C. J., Sanna, S., Jackson, A. U., Scuteri, A., Bonnycastle, L. L., Clarke, R., Heath, S. C., Timpson, N. J., Najjar, S. S., Stringham, H. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.76 · Cited by 1,585 · see citing works
Subendothelial Lipoprotein Retention as the Initiating Process in Atherosclerosis: Update and Therapeutic Implications
Tabas, I., Williams, K. J., & Borén, J. (2007) · Circulation · doi:10.1161/circulationaha.106.676890 · Cited by 1,399 · see citing works
Cholesterol in the Prediction of Atherosclerotic Disease
Kannel, W. B., Castelli, W. P., & Gordon, T. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-90-1-85 · Cited by 1,314 · see citing works
High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study
Walldius, G., Jungner, I., Holme, I., AASTVEIT, A. H., Kolar, W., & Steiner, E. (2001) · The Lancet · doi:10.1016/s0140-6736(01)07098-2 · Cited by 1,227 · see citing works
A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction.
Stampfer, M. J., Sacks, F. M., Salvini, S., Willett, W. C., & Hennekens, C. H. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108083250601 · Cited by 1,163 · see citing works
Coronary Heart Disease Prediction From Lipoprotein Cholesterol Levels, Triglycerides, Lipoprotein(a), Apolipoproteins A-I and B, and HDL Density Subfractions
Sharrett, A. R., Ballantyne, C. M., Coady, S., HEISS, G. M., Sorlie, P. D., Catellier, D., & Patsch, W. (2001) · Circulation · doi:10.1161/hc3501.095214 · Cited by 942 · see citing works
Non–HDL Cholesterol, Apolipoproteins A-I and B <sub>100</sub> , Standard Lipid Measures, Lipid Ratios, and CRP as Risk Factors for Cardiovascular Disease in Women
Ridker, P. M., Rifai, N., Cook, N. R., Bradwin, G., & Buring, J. E. (2005) · JAMA · doi:10.1001/jama.294.3.326 · Cited by 744 · see citing works
Lipoprotein Particle Analysis by Nuclear Magnetic Resonance Spectroscopy
Jeyarajah, E. J., Cromwell, W. C., & Otvos, J. D. (2006) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2006.07.006 · Cited by 735 · see citing works
Lipoprotein Management in Patients With Cardiometabolic Risk
Brunzell, J. D., Davidson, M. H., Furberg, C. D., Goldberg, R. B., Howard, B. V., Stein, J. H., & Witztum, J. L. (2008) · Diabetes Care · doi:10.2337/dc08-9018 · Cited by 710 · see citing works
Complete protein sequence and identification of structural domains of human apolipoprotein B
Knott, T. J., Pease, R. J., Powell, L. M., Wallis, S. C., Rall, S. C., Innerarity, T. L., Blackhart, B. D., Taylor, W. H., Marcel, Y. L., Milne, R. W., et al. (1986) · Nature · doi:10.1038/323734a0 · Cited by 619 · see citing works
Lipoprotein Changes and Reduction in the Incidence of Major Coronary Heart Disease Events in the Scandinavian Simvastatin Survival Study (4S)
Pedersen, T. R., OLSSON, A. G., Færgeman, O., KJEKSHUS, J. K., Wedel, H., Berg, K., Wilhelmsen, L., Haghfelt, T. H., Þorgeirsson, G., Pyörälà, K., et al. (1998) · Circulation · doi:10.1161/01.cir.97.15.1453 · Cited by 618 · see citing works
Clinical utility of different lipid measures for prediction of coronary heart disease in men and women
Ingelsson, E., Schaefer, E. J., Contois, J. H., McNamara, J. R., Sullivan, L., Keyes, M. J., Pencina, M. J., Schoonmaker, C., Wilson, P. W. F., D’Agostino, R. B., et al. (2007) · JAMA · doi:10.1001/jama.298.7.776 · Cited by 608 · see citing works
Self-citation
Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly
Hussain, M. M., Shi, J., & Dreizen, P. (2003) · Journal of Lipid Research · doi:10.1194/jlr.r200014-jlr200 · Cited by 591 · see citing works
Estimating low-density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints
Warnick, G. R., Knopp, R. H., Fitzpatrick, V., & Branson, L. F. (1990) · Clinical Chemistry · doi:10.1093/clinchem/36.1.15 · Cited by 568 · see citing works
Self-citation
Relation Between Baseline and On-Treatment Lipid Parameters and First Acute Major Coronary Events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
Gotto, A. M., Whitney, E. J., Stein, E. A., Shapiro, D. R., Clearfield, M. B., Weis, S. E., Jou, J. Y., Langendörfer, A., Beere, P. A., Watson, D. J., et al. (2000) · Circulation · doi:10.1161/01.cir.101.5.477 · Cited by 562 · see citing works
Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial
Otvos, J. D., Collins, D. E., Freedman, D. S., SHALAUROVA, I. Y., Schaefer, E. J., McNamara, J. R., Bloomfield, H. E., & Robins, S. J. (2006) · Circulation · doi:10.1161/circulationaha.105.565135 · Cited by 542 · see citing works
High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study
Walldius, G., Jungner, I., Holme, I., AASTVEIT, A. H., Kolar, W., & Steiner, E. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00666-9 · Cited by 534 · see citing works
Lipoprotein Management in Patients With Cardiometabolic Risk
Brunzell, J. D., Davidson, M. H., Furberg, C. D., Goldberg, R. B., Howard, B. V., Stein, J. H., & Witztum, J. L. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.02.034 · Cited by 523 · see citing works
Structure of apolipoprotein B-100 in low density lipoproteins
Segrest, J. P., Jones, M. K., Loof, H. D., & Dashti, N. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)30267-4 · Cited by 523 · see citing works
Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men
Pischon, T., Girman, C. J., Sacks, F. M., Rifai, N., Stampfer, M. J., & Rimm, E. B. (2005) · Circulation · doi:10.1161/circulationaha.104.532499 · Cited by 514 · see citing works
Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding.
Innerarity, T. L., Weisgraber, K. H., Arnold, K. S., Mahley, R. W., Krauss, R. M., Vega, G. L., & Grundy, S. M. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.19.6919 · Cited by 491 · see citing works
Apolipoprotein A-I and B Levels and the Risk of Ischemic Heart Disease During a Five-Year Follow-up of Men in the Que´bec Cardiovascular Study
Lamarche, B., Moorjani, S., Lupien, P. J., Cantin, B., Bernard, P.-M., Dagenais, G. R., & Despre´s, J.-P. (1996) · Circulation · doi:10.1161/01.cir.94.3.273 · Cited by 476 · see citing works
Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty‐person/ten‐country panel
Barter, P. J., Ballantyne, C. M., Carmena, R., Cabezas, M. C., Chapman, M. J., Couture, P., Graaf, J. D., Durrington, P. N., Færgeman, O., Frohlich, J., et al. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01616.x · Cited by 463 · see citing works
Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment
Sniderman, A. D., Furberg, C. D., KEECH, A. C., van Lennep, J. R., Frohlich, J., Jungner, I., & Walldius, G. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12663-3 · Cited by 457 · see citing works
Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation
Nauck, M., Warnick, G. R., & Rifai, N. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.2.236 · Cited by 442 · see citing works
Self-citation
LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study—Implications for LDL management
Cromwell, W. C., Otvos, J. D., Keyes, M. J., Pencina, M. J., SULLIVAN, L. M., Vasan, R. S., Wilson, P. W. F., & D’Agostino, R. B. (2007) · Journal of clinical lipidology · doi:10.1016/j.jacl.2007.10.001 · Cited by 428 · see citing works
Low-Density Lipoprotein Subfractions and the Long-Term Risk of Ischemic Heart Disease in Men: 13-Year Follow-Up Data From the Québec Cardiovascular Study
St-Pierre, A. C., Cantin, B., Dagenais, G. R., Mauriège, P., Bernard, P.-M., Després, J.-P., & Lamarche, B. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000154144.73236.f4 · Cited by 422 · see citing works
Recent progress in understanding apolipoprotein B.
Young, S. G. (1990) · Circulation · doi:10.1161/01.cir.82.5.1574 · Cited by 421 · see citing works
Low-Density Lipoprotein Particle Concentration and Size as Determined by Nuclear Magnetic Resonance Spectroscopy as Predictors of Cardiovascular Disease in Women
Blake, G. J., Otvos, J. D., Rifai, N., & Ridker, P. M. (2002) · Circulation · doi:10.1161/01.cir.0000033222.75187.b9 · Cited by 409 · see citing works
Apolipoprotein B and apolipoprotein A‐I: risk indicators of coronary heart disease and targets for lipid‐modifying therapy
Walldius, G., & Jungner, I. (2004) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2003.01276.x · Cited by 395 · see citing works
LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA)
Mora, S., Szklo, M., Otvos, J. D., Greenland, P., Psaty, B. M., Goff, D. C., O’Leary, D. H., Saad, M. F., Tsai, M. Y., & Sharrett, A. R. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.05.007 · Cited by 380 · see citing works
A status report
Bigelow, R. P. (1992) · Computer Law & Security Report · doi:10.1016/0267-3649(92)90026-6 · Cited by 358 · see citing works
Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update.
Genest, J. J., Frohlich, J. J., Fodor, G. J., & McPherson, R. (2003) · PubMed Central · Cited by 345 · see citing works
International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material
Marcovina, S. M., Albers, J. J., Henderson, L. O., & Hannon, W. H. (1993) · Clinical Chemistry · doi:10.1093/clinchem/39.5.773 · Cited by 342 · see citing works
Selective Retention of VLDL, IDL, and LDL in the Arterial Intima of Genetically Hyperlipidemic Rabbits In Vivo: Molecular Size as a Determinant of Fractional Loss From the Intima–Inner Media
Nordestgaard, B. G., Wootton, R., & Lewis, B. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.4.534 · Cited by 334 · see citing works
Nuclear Magnetic Resonance Spectroscopy of Lipoproteins and Risk of Coronary Heart Disease in the Cardiovascular Health Study
Kuller, L. H., Arnold, A. M., Tracy, R. P., Otvos, J. D., Burke, G. L., Psaty, B. M., Siscovick, D. S., Freedman, D. S., & Kronmal, R. A. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000022015.97341.3a · Cited by 310 · see citing works
Low-Density Lipoprotein, Non-High-Density Lipoprotein, and Apolipoprotein B as Targets of Lipid-Lowering Therapy
Grundy, S. M. (2002) · Circulation · doi:10.1161/01.cir.0000038419.53000.d6 · Cited by 309 · see citing works
Sex and Age Differences in Lipoprotein Subclasses Measured by Nuclear Magnetic Resonance Spectroscopy: The Framingham Study
Freedman, D. S., Otvos, J. D., Jeyarajah, E. J., SHALAUROVA, I. Y., Cupples, L. A., Parise, H., D’Agostino, R. B., Wilson, P. W. F., & Schaefer, E. J. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2004.032763 · Cited by 304 · see citing works
Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the pravastatin limitation of atherosclerosis in the coronary arteries (PLAC-I) trial
Rosenson, R. S., Otvos, J. D., & Freedman, D. S. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02427-x · Cited by 293 · see citing works
Thrombogenic Factors and Recurrent Coronary Events
Moss, A. J., Goldstein, R. E., Marder, V. J., Sparks, C. E., Oakes, D., Greenberg, H., Weiss, H. J., Zaręba, W., Brown, M. W., Liang, C., et al. (1999) · Circulation · doi:10.1161/01.cir.99.19.2517 · Cited by 281 · see citing works
Relationships Between Low-Density Lipoprotein Particle Size, Plasma Lipoproteins, and Progression of Coronary Artery Disease
Vakkilainen, J., Steiner, G. A., Ansquer, J.-C., Aubin, F., Rattier, S., Foucher, C., Hamsten, A., & Taskinen, M. (2003) · Circulation · doi:10.1161/01.cir.0000057982.50167.6e · Cited by 270 · see citing works
Plasma very low density lipoproteins contain a single molecule of apolipoprotein B
Elovson, J., Chatterton, J. E., Bell, G. T., Schumaker, V. N., Reuben, M. A., Puppione, D. L., Reeve, J. R., & Young, N. L. (1988) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38425-x · Cited by 266 · see citing works
Serum fatty acids, apolipoproteins, selenium and vitamin antioxidants and the risk of death from coronary artery disease
Salonen, J. T., Salonen, R. M., Penttilä, I., Herranen, J., Jauhiainen, M., Kantola, M., Lappeteläinen, R., Mäenpää, P. H., Alfthan, G., & Puska, P. (1985) · The American Journal of Cardiology · doi:10.1016/0002-9149(85)90839-2 · Cited by 264 · see citing works
Evidence for a New Pathophysiological Mechanism for Coronary Artery Disease Regression: Hepatic Lipase–Mediated Changes in LDL Density
Zambon, A., Hokanson, J. E., Brown, B. G., & Brunzell, J. D. (1999) · Circulation · doi:10.1161/01.cir.99.15.1959 · Cited by 263 · see citing works
Comparison of Various Electrophoretic Characteristics of LDL Particles and Their Relationship to the Risk of Ischemic Heart Disease
St-Pierre, A., Ruel, I. L., Cantin, B., Dagenais, G. R., Bernard, P., Després, J., & Lamarche, B. (2001) · Circulation · doi:10.1161/hc4401.098490 · Cited by 259 · see citing works
Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies
THOMPSON, A., & DANESH, J. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01644.x · Cited by 252 · see citing works
Relationship Between Lipid Levels and Clinical Outcomes in the Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) Trial
Simes, R. J., Marschner, I. C., Hunt, D. U., Colquhoun, D., SULLIVAN, D. R., Stewart, R., Hague, W. E., KEECH, A. C., Thompson, P., White, H. D., et al. (2002) · Circulation · doi:10.1161/hc1002.105136 · Cited by 250 · see citing works
International federation of clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of international reference material
Marcovina, S. M., Albers, J. J., Kennedy, H., Mei, J. V., Henderson, L. O., & Hannon, W. H. (1994) · Clinical Chemistry · doi:10.1093/clinchem/40.4.586 · Cited by 243 · see citing works
Composition and distribution of low density lipoprotein fractions in hyperapobetalipoproteinemia, normolipidemia, and familial hypercholesterolemia.
Teng, B., Thompson, G. R., Sniderman, A. D., Forte, T. M., Krauss, R. M., & Kwiterovich, P. O. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.21.6662 · Cited by 242 · see citing works
Apolipoproteins and ischaemic heart disease: implications for screening
Wald, N., Watt, H., Bailey, A., Johnson, M., Ledue, T. B., & Haddow, J. E. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90814-1 · Cited by 241 · see citing works
Value of Low-Density Lipoprotein Particle Number and Size as Predictors of Coronary Artery Disease in Apparently Healthy Men and Women
El Harchaoui, K., van der Steeg, W. A., Stroes, E. S. G., Kuivenhoven, J. A., Otvos, J. D., Wareham, N. J., Hutten, B. A., Kastelein, J. J. P., Khaw, K.-T., & Boekholdt, S. M. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.09.043 · Cited by 239 · see citing works
Structure of the human apolipoprotein B gene.
Blackhart, B. D., Ludwig, E. H., Pierotti, V., CAIATI, L., Onasch, M. A., Wallis, S. C., Powell, L., Pease, R. J., Knott, T. J., & Chu, M. L. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)66718-3 · Cited by 236 · see citing works
Multivariate Assessment of Lipid Parameters as Predictors of Coronary Heart Disease Among Postmenopausal Women
Shai, I., Rimm, E. B., Hankinson, S. E., Curhan, G. C., Manson, J. E., Rifai, N., Stampfer, M. J., & Ma, J. (2004) · Circulation · doi:10.1161/01.cir.0000146339.57154.9b · Cited by 235 · see citing works
Nonfasting Apolipoprotein B and Triglyceride Levels as a Useful Predictor of Coronary Heart Disease Risk in Middle-Aged UK Men
Talmud, P. J., Hawe, E., Miller, G. J., & Humphries, S. E. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000035521.22199.c7 · Cited by 233 · see citing works
Non-HDL Cholesterol and Apolipoprotein B Predict Cardiovascular Disease Events Among Men With Type 2 Diabetes
Jiang, R., Schulze, M. B., Li, T., Rifai, N., Stampfer, M. J., Rimm, E. B., & Hu, F. B. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.1991 · Cited by 232 · see citing works
Apolipoprotein B, the major protein component of triglyceride-rich and low density lipoproteins.
Chan, L. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)35646-1 · Cited by 231 · see citing works
Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study
Contois, J. H., McNamara, J. R., Lammi‐Keefe, C. J., Wilson, P. W. F., Massov, T., & Schaefer, E. J. (1996) · Clinical Chemistry · doi:10.1093/clinchem/42.4.515 · Cited by 231 · see citing works
Self-citation
International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B
Marcovina, S. M., Albers, J. J., Dati, F., Ledue, T. B., & Ritchie, R. F. (1991) · Clinical Chemistry · doi:10.1093/clinchem/37.10.1676 · Cited by 228 · see citing works
Direct Determination of Lipoprotein Particle Sizes and Concentrations by Ion Mobility Analysis
Caulfield, M. P., Li, S., Lee, G. S., Blanche, P. J., Salameh, W. A., Benner, W. H., Reitz, R. E., & Krauss, R. M. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2007.100586 · Cited by 227 · see citing works
Calculated values for low-density lipoprotein cholesterol in the assessment of lipid abnormalities and coronary disease risk
McNamara, J. R., Cohn, J. S., Wilson, P. W. F., & Schaefer, E. J. (1990) · Clinical Chemistry · doi:10.1093/clinchem/36.1.36 · Cited by 210 · see citing works
The importance of non–HDL cholesterol reporting in lipid management
Blaha, M. J., Blumenthal, R. S., Brinton, E. A., & Jacobson, T. A. (2008) · Journal of clinical lipidology · doi:10.1016/j.jacl.2008.06.013 · Cited by 193 · see citing works
Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men
Sigurðsson, G., Baldursdóttir, Á., Sigvaldason, H., Agnarsson, U., Þorgeirsson, G., & Sigfússon, N. (1992) · The American Journal of Cardiology · doi:10.1016/0002-9149(92)91215-p · Cited by 187 · see citing works
Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels
Marcovina, S. M., & Packard, C. J. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01648.x · Cited by 180 · see citing works
Measurement of low-density-lipoprotein cholesterol in serum: a status report
Rifai, N., Warnick, G. R., McNamara, J. R., Belcher, J. D., Grinstead, G. F., & Frantz, I. D. (1992) · Clinical Chemistry · doi:10.1093/clinchem/38.1.150 · Cited by 169 · see citing works
Self-citation
Apolipoprotein Concentrations During Treatment and Recurrent Coronary Artery Disease Events
van Lennep, J. E. R., Westerveld, H. T., van Lennep, H. W. O. R., Zwinderman, A. H., Erkelens, D. W., & van der Wall, E. E. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.11.2408 · Cited by 152 · see citing works
Improving Prediction of Ischemic Cardiovascular Disease in the General Population Using Apolipoprotein B
Benn, M., Nordestgaard, B. G., Jensen, G. B., & Tybjærg‐Hansen, A. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000255580.73689.8e · Cited by 152 · see citing works
Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study
Meisinger, C., Loewel, H., Wilfried, M. R. A. Z., & Köenig, W. (2004) · European Heart Journal · doi:10.1093/eurheartj/ehi003 · Cited by 142 · see citing works
The Friedewald Formula Underestimates LDL Cholesterol at low Concentrations
Scharnagl, H., Nauck, M. A., Wieland, H., & März, W. (2001) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2001.068 · Cited by 140 · see citing works
N-terminal domain of apolipoprotein B has structural homology to lipovitellin and microsomal triglyceride transfer protein: a “lipid pocket” model for self-assembly of apoB-containing lipoprotein particles
Segrest, J. P., Jones, M. K., & Dashti, N. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33382-4 · Cited by 128 · see citing works
Nomogram to Diagnose Familial Combined Hyperlipidemia on the Basis of Results of a 5-Year Follow-Up Study
Veerkamp, M. J., Graaf, J. D., Hendriks, J. C. M., Demacker, P. N. M., & Stalenhoef, A. F. H. (2004) · Circulation · doi:10.1161/01.cir.0000130646.93255.86 · Cited by 128 · see citing works
Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice
Sniderman, A. D. (2008) · Journal of clinical lipidology · doi:10.1016/j.jacl.2007.12.006 · Cited by 116 · see citing works
Ten-year follow-up results from the Goettingen Risk, Incidence and Prevalence Study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 men
Cremer, P., Nagel, D., Mann, H., Labrot, B., Müller-Berninger, R., Elster, H., & Seidel, D. (1997) · Atherosclerosis · doi:10.1016/s0021-9150(96)06030-3 · Cited by 108 · see citing works
Performance of Four Homogeneous Direct Methods for LDL-Cholesterol
Miller, W. G., Waymack, P. P., Anderson, F. P., Ethridge, S. F., & Jayne, E. C. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.3.489 · Cited by 104 · see citing works
International Federation of Clinical Chemistry Standardization Project for Measurements of Apolipoproteins A-I and B. II. Evaluation and Selection of Candidate Reference Materials
Albers, J. J., Marcovina, S. M., & Kennedy, H. (1992) · Clinical Chemistry · doi:10.1093/clinchem/38.5.658 · Cited by 103 · see citing works
Relative Atherogenicity and Predictive Value of Non–High-Density Lipoprotein Cholesterol for Coronary Heart Disease
Miller, M., Ginsberg, H. N., & Schaefer, E. J. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.11.046 · Cited by 102 · see citing works
Measurement of triglyceride-rich lipoproteins by nuclear magnetic resonance spectroscopy
Otvos, J. D. (1999) · Clinical Cardiology · doi:10.1002/clc.4960221405 · Cited by 89 · see citing works
APO B gene polymorphisms and coronary artery disease: a meta-analysis
Chiodini, B. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(02)00425-2 · Cited by 89 · see citing works
Effect of moderate hypertriglyceridemia on the relation of plasma total and LDL apo B levels
Sniderman, A. D., Vu, H., & Cianflone, K. (1991) · Atherosclerosis · doi:10.1016/0021-9150(91)90050-d · Cited by 81 · see citing works
The Amino Terminus of Apolipoprotein B Is Necessary but Not Sufficient for Microsomal Triglyceride Transfer Protein Responsiveness
Gretch, D. G., Sturley, S. L., Wang, L., Lipton, B. A., Dunning, A. M., Grunwald, K. A. A., Wetterau, J. R., Yao, Z., Talmud, P. J., & Attie, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.15.8682 · Cited by 76 · see citing works
Atherogenic lipoprotein phenotype and LDL size and subclasses in patients with peripheral arterial disease
Rizzo, M., Pernice, V., Frasheri, A., & Berneis, K. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.03.034 · Cited by 75 · see citing works
Missense Mutations in APOB within the βα1 Domain of Human APOB-100 Result in Impaired Secretion of ApoB and ApoB-containing Lipoproteins in Familial Hypobetalipoproteinemia
Burnett, J. R., Zhong, S., Jiang, Z. G., Hooper, A. J., Fisher, E. A., McLeod, R. S., Zhao, Y., Barrett, P. H. R., Hegele, R. A., BOCKXMEER, F. M. V., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702442200 · Cited by 71 · see citing works
A prospective study of obesity, lipids, apolipoproteins and ischaemic heart disease in women
Coleman, M. P., Key, T. J. A., Wang, D. Y., Hermon, C., Fentiman, I. S., Allen, D., Jarvis, M. J., Pike, M. C., & Sanders, T. A. B. (1992) · Atherosclerosis · doi:10.1016/0021-9150(92)90276-m · Cited by 62 · see citing works
Molecular variation at the apolipoprotein�B gene locus in relation to lipids and cardiovascular disease: a systematic meta-analysis
Boekholdt, S. M., Peters, R. J. G., Fountoulaki, K., Kastelein, J. J. P., & Sijbrands, E. J. G. (2003) · Human Genetics · doi:10.1007/s00439-003-0988-3 · Cited by 61 · see citing works
Assessment of Reaching Goal in Patients with Combined Hyperlipidemia: Low-Density Lipoprotein Cholesterol, Non–High-Density Lipoprotein Cholesterol, or Apolipoprotein B
Stein, E. A., Sniderman, A. D., & Laskarzewski, P. M. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.08.006 · Cited by 58 · see citing works
Apolipoprotein B-containing Lipoprotein Particle Assembly
Manchekar, M., Richardson, P. E., Forte, T. M., Datta, G., Segrest, J. P., & Dashti, N. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406302200 · Cited by 58 · see citing works
Apolipoproteins A–I, A–II and B, lipoprotein(a) and the risk of ischaemic heart disease: the Caerphilly Study
Sweetnam, P. M., Bolton, C., Downs, L. G., Durrington, P. N., Mackness, M., Elwood, P. C., & Yarnell, J. W. G. (2000) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2000.00725.x · Cited by 50 · see citing works
Apolipoprotein B determines risk for recurrent coronary events in postinfarction patients with metabolic syndrome
Corsetti, J. P., Zaręba, W., Moss, A. J., & Sparks, C. E. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.07.019 · Cited by 43 · see citing works
Effect of balloon inflation‐induced acute ischemia on QT dispersion during percutaneous transluminal coronary angioplasty
Aytemir, K., Bavafa, V., Ozer, N., Aksöyek, S., Oto, A., & Özmen, F. (1999) · Clinical Cardiology · doi:10.1002/clc.4960220109 · Cited by 42 · see citing works
Genetics of apolipoprotein B and apolipoprotein AI and premature coronary artery disease
Zambon, A., Brown, B. G., Deeb, S. S., & Brunzell, J. D. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01645.x · Cited by 38 · see citing works
Lipoprotein heterogeneity: diagnostic and therapeutic implications
Kwiterovich, P. O. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02796-0 · Cited by 33 · see citing works
Risk factors for acute myocardial infarction in the elderly (the Dubbo study)
Simons, L. A., Simons, J., Friedlander, Y., & McCallum, J. C. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)02168-3 · Cited by 19 · see citing works
Is LDL-C Passed Its Prime?
Davidson, M. H. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.172718 · Cited by 19 · see citing works
Polymorphisms in Apolipoprotein B and Risk of Ischemic Stroke
Benn, M., Nordestgaard, B. G., Jensen, J. S., & Tybjærg‐Hansen, A. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0221 · Cited by 18 · see citing works
Non—HDL Cholesterol, Apolipoproteins A-1 and B100, Standard Lipid Measures, Lipid Ratios, and CRP as Risk Factors for Cardiovascular Disease in Women
Howard, W. J. (2006) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)70303-2 · Cited by 15 · see citing works
A Prospective Comparison of NMR-Measured LDL Particle Number, Apolipoprotein B100, and Standard Lipids with Incident CHD in 27,673 Initially Healthy Women
Mora, S. (2007) · Circulation · doi:10.1161/circ.116.suppl_16.ii_v-b · Cited by 3 · see citing works
Introduction
Goldstein, B. J. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02552-3 · Cited by 3 · see citing works

Flagged first, then by citations

Research works printed but not linked: 1

[14]14. Rudd JH, Davies JR, Weissberg PL. Chapter 1: Atherosclerotic biology and epidemiology of dis-

Sorted by citations

Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J. P., Dralle, H., Ebeling, P. R., Melmed, S. K., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,473 · see citing works
Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer
Francis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C., Hamilton, J. K., HAY, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,252 · see citing works
Assessment of Cardiovascular Risk and Prevention of Cardiovascular Disease in Women with the Polycystic Ovary Syndrome: A Consensus Statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society
Wild, R. A., Carmina, E., Diamanti-Kandarakis, E., Dokras, A., Escobar-Morreale, H. F., Futterweit, W., Lobo, R., Norman, R. J., Talbott, E., & Dumesic, D. A. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2724 · Cited by 1,010 · see citing works
A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk
Sniderman, A. D., Williams, K., Contois, J. H., Monroe, H. M., McQueen, M. J., de Graaf, J., & Furberg, C. D. (2011) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.110.959247 · Cited by 659 · see citing works
Self-citation
Indian Journal of Public Health Research & Development
Surwade, V. M., Ambedkar, B. S., Rohinee, & Delhi (2019) · Cited by 404 · see citing works
The oil spill in ageing Bruch membrane
Curcio, C. A., Johnson, M. F., Rudolf, M., & Huang, J.-D. (2011) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2011-300344 · Cited by 392 · see citing works
Exploiting the GTEx resources to decipher the mechanisms at GWAS loci
Barbeira, A., Bonazzola, R., Gamazon, E. R., Liang, Y., Park, Y., Kim-Hellmuth, S., Wang, G. T., Jiang, Z., Zhou, D., Hormozdiari, F., et al. (2021) · Genome biology · doi:10.1186/s13059-020-02252-4 · Cited by 307 · see citing works
Dyslipidemia in Type 2 Diabetes: Prevalence, Pathophysiology, and Management
Chehade, J. M., Gladysz, M., & Mooradian, A. D. (2013) · Drugs · doi:10.1007/s40265-013-0023-5 · Cited by 299 · see citing works
Aging, age-related macular degeneration, and the response-to-retention of apolipoprotein B-containing lipoproteins
Curcio, C. A., Johnson, M., Huang, J.-D., & Rudolf, M. (2009) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2009.08.001 · Cited by 286 · see citing works
Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target
Behbodikhah, J., Ahmed, S., Elyasi, A., Kasselman, L. J., Leon, J. D., Glass, A. D., & Reiss, A. B. (2021) · Metabolites · doi:10.3390/metabo11100690 · Cited by 284 · see citing works
Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease
Rosenson, R. S., Davidson, M. H., Hirsh, B. J., Kathiresan, S., & Gaudet, D. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.042 · Cited by 260 · see citing works
Effects of an isocaloric healthy N ordic diet on insulin sensitivity, lipid profile and inflammation markers in metabolic syndrome – a randomized study ( SYSDIET )
Uusitupa, M. I. J., Hermansen, K., Savolainen, M. J., Schwab, U., Kolehmainen, M., Brader, L., Mortensen, L. S., Cloetens, L., Johansson‐Persson, A., Önning, G., et al. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12044 · Cited by 267 · see citing works
Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists
Davidson, M. H., Ballantyne, C. M., Jacobson, T. A., Bittner, V. A., Braun, L. T., Brown, A. S., Brown, W. V., Cromwell, W. C., Goldberg, R. B., McKenney, J. M., et al. (2011) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.07.005 · Cited by 262 · see citing works
Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM
Langlois, M. R., Chapman, M. J., Cobbaert, C., Mora, S., Remaley, A. T., Ros, E., Watts, G. F., Borén, J., Baum, H., Bruckert, E., et al. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2018.287037 · Cited by 260 · see citing works
Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey
KONES, R. J. (2011) · Drug Design Development and Therapy · doi:10.2147/dddt.s14934 · Cited by 257 · see citing works
Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events
Mora, S., Buring, J. E., & Ridker, P. M. (2014) · Circulation · doi:10.1161/circulationaha.113.005873 · Cited by 255 · see citing works
Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM
Nordestgaard, B. G., Langlois, M. R., Langsted, A., Chapman, M. J., Aakre, K. M., Baum, H., Borén, J., Bruckert, E., Catapano, A., Cobbaert, C., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.12.005 · Cited by 240 · see citing works
Apolipoproteins: metabolic role and clinical biochemistry applications
Dominiczak, M. H., & Caslake, M. J. (2011) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1258/acb.2011.011111 · Cited by 238 · see citing works
The effects of exercise training on lipid metabolism and coronary heart disease
Muscella, A., Stefàno, E., & Marsigliante, S. (2020) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00708.2019 · Cited by 245 · see citing works
Lipid parameters for measuring risk of cardiovascular disease
Arsenault, B. J., Boekholdt, S. M., & Kastelein, J. J. P. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.223 · Cited by 228 · see citing works
American Association of Clinical Endocrinologists’ Comprehensive Diabetes Management Algorithm 2013 Consensus Statement
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S. E., Davidson, M., EINHORN, D. F., Garvey, W. T., et al. (2013) · Endocrine Practice · doi:10.4158/ep13176.csuppl · Cited by 219 · see citing works
Why Guideline-Making Requires Reform
Sniderman, A. D. (2009) · JAMA · doi:10.1001/jama.2009.15 · Cited by 217 · see citing works
Lipids and Lipoproteins and Risk of Different Vascular Events in the MRC/BHF Heart Protection Study
Parish, S., Offer, A. R., Clarke, R., Hopewell, J. C., Hill, M., Otvos, J. D., Armitage, J., & Collins, R. (2012) · Circulation · doi:10.1161/circulationaha.111.073684 · Cited by 211 · see citing works
Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM
Langlois, M. R., Nordestgaard, B. G., Langsted, A., Chapman, M. J., Aakre, K. M., Baum, H., Borén, J., Bruckert, E., Catapano, A., Cobbaert, C., et al. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2019-1253 · Cited by 211 · see citing works
Liposcale: a novel advanced lipoprotein test based on 2D diffusion-ordered 1H NMR spectroscopy
Mallol, R., Amigó, N., Rodriguez, M. A., Heras, M., Vinaixa, M., Plana, N., Rock, E., Ribalta, J., Yanes, Ó., Masana, L., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.d050120 · Cited by 199 · see citing works
APOBEC: A molecular driver in cervical cancer pathogenesis
Revathidevi, S., Murugan, A. K., Nakaoka, H., Inoue, I., & Munirajan, A. K. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.10.004 · Cited by 226 · see citing works
Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment
Carr, S. S., Hooper, A. J., SULLIVAN, D. R., & Burnett, J. R. (2018) · Pathology · doi:10.1016/j.pathol.2018.11.006 · Cited by 197 · see citing works
Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease: Data From UK Biobank
Welsh, C., Celis-Morales, C. A., Brown, R., Mackay, D. F., Lewsey, J., Mark, P. B., Gray, S. R., Ferguson, L. D., Anderson, J. J., Lyall, D. M., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.041149 · Cited by 191 · see citing works
Nonfasting versus fasting lipid profile for cardiovascular risk prediction
Langsted, A., & Nordestgaard, B. G. (2019) · Pathology · doi:10.1016/j.pathol.2018.09.062 · Cited by 191 · see citing works
NMR measurement of LDL particle number using the Vantera® Clinical Analyzer
Matyus, S. P., Braun, P. J., Wolak, J. E., Jeyarajah, E. J., SHALAUROVA, I. Y., Xu, Y., Warner, S. M., Clement, T. S., Connelly, M. A., & Fischer, T. J. (2014) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2014.07.015 · Cited by 169 · see citing works
Structure, Function, and Pathology of Bruch's Membrane
Curcio, C. A., & Johnson, M. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0737-9.00020-5 · Cited by 169 · see citing works
Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C
Pencina, M. J., D’Agostino, R. B., Zdrojewski, T., Williams, K., Thanassoulis, G., Furberg, C. D., Peterson, E. D., Vasan, R. S., & Sniderman, A. D. (2015) · European Journal of Preventive Cardiology · doi:10.1177/2047487315569411 · Cited by 164 · see citing works
Non–High-Density Lipoprotein Cholesterol Versus Apolipoprotein B in Cardiovascular Risk Stratification
Ramjee, V., Sperling, L. S., & Jacobson, T. A. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.05.009 · Cited by 157 · see citing works
PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021
Banach, M., Burchardt, P., Chlebus, K., Dobrowolski, P., Dudek, D., Dyrbuś, K., Gąsior, M., Jankowski, P., Jozwiak, J. J., Kłosiewicz−Latoszek, L., et al. (2021) · Archives of Medical Science · doi:10.5114/aoms/141941 · Cited by 163 · see citing works
Simultaneous Quantification of Apolipoprotein A-I and Apolipoprotein B by Liquid-Chromatography–Multiple- Reaction–Monitoring Mass Spectrometry
Agger, S. A., Marney, L. C., & Hoofnagle, A. N. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2010.152264 · Cited by 143 · see citing works
An adverse lipid profile is associated with disability and progression in disability, in people with MS
Tettey, P., Simpson, S., Taylor, B. V., Blizzard, L., Ponsonby, A., Dwyer, T., Kostner, K., & van der Mei, I. A. F. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458514533162 · Cited by 142 · see citing works
Lipids, Lipoproteins, Apolipoproteins, and Other Cardiovascular Risk Factors
Remaley, A. T., Rifai, N., & Warnick, G. R. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6164-9.00027-5 · Cited by 139 · see citing works
Self-citation
Functions and Malfunctions of Mammalian DNA-Cytosine Deaminases
Siriwardena, S. U., Chen, K., & Bhagwat, A. S. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00296 · Cited by 138 · see citing works
Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group
Wilson, P. W. F., Jacobson, T. A., Martin, S. S., Jackson, E. J., Le, N., Davidson, M. H., Vesper, H. W., Frikke‐Schmidt, R., Ballantyne, C. M., & Remaley, A. T. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.09.046 · Cited by 134 · see citing works
Reliability of low-density lipoprotein cholesterol, non-high density lipoprotein cholesterol, and apolipoprotein B measurement
Contois, J. H., Warnick, G. R., & Sniderman, A. D. (2011) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.05.004 · Cited by 123 · see citing works
Self-citation
Association of apolipoprotein B and nuclear magnetic resonance spectroscopy-derived LDL particle number with outcomes in 25 clinical studies: assessment by the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices
Cole, T. G., Contois, J. H., Csako, G., McConnell, J. P., Remaley, A. T., Devaraj, S., Hoefner, D. M., Mallory, T., Sethi, A. A., & Warnick, G. R. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2012.196733 · Cited by 122 · see citing works
Self-citation
Diagnosis and treatment of apolipoprotein B dyslipoproteinemias
Sniderman, A. D., Couture, P., & Graaf, J. D. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.50 · Cited by 118 · see citing works
Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention
Sniderman, A. D., Dufresne, L., Pencina, K. M., Bilgic, S., Thanassoulis, G., & Pencina, M. J. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae258 · Cited by 117 · see citing works
Effect of a 6-month vegan low-carbohydrate (‘Eco-Atkins’) diet on cardiovascular risk factors and body weight in hyperlipidaemic adults: A randomised controlled trial
Jenkins, D. J. A., Wong, J. M. W., Kendall, C. W. C., Esfahani, A., Ng, V. W. Y., Leong, T. C. K., Faulkner, D. A., Vidgen, E., Paul, G., Mukherjea, R., et al. (2014) · BMJ Open · doi:10.1136/bmjopen-2013-003505 · Cited by 109 · see citing works
The Role of Lipids and Lipoproteins in Atherosclerosis
Linton, M. F., Yancey, P. G., Davies, S. S., Jerome, W. G., Linton, E. F., Song, W., Doran, A. C., & Vickers, K. C. (2015) · Europe PMC (PubMed Central) · Cited by 108 · see citing works
A Ketogenic Low-Carbohydrate High-Fat Diet Increases LDL Cholesterol in Healthy, Young, Normal-Weight Women: A Randomized Controlled Feeding Trial
Burén, J., Ericsson, M., Damasceno, N., & Sjödin, A. (2021) · Nutrients · doi:10.3390/nu13030814 · Cited by 104 · see citing works
Apolipoprotein B/A-I and total cholesterol/high-density lipoprotein cholesterol ratios both predict cardiovascular events in the general population independently of nonlipid risk factors, albuminuria and C-reactive protein
Kappelle, P. J. W. H., Gansevoort, R. T., Hillege, J. L., Wolffenbuttel, B. H. R., Dullaart, R. P. F., & on behalf of the PREVEND study group (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02323.x · Cited by 97 · see citing works
Dyslipidaemia in Rheumatological Autoimmune Diseases
Toms, T. E., Panoulas, V. F., & Kitas, G. D. (2011) · The Open Cardiovascular Medicine Journal · doi:10.2174/1874192401105010064 · Cited by 95 · see citing works
Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes
on behalf of the FIELD study investigators, Taskinen, M.-R., Barter, P. J., Ehnholm, C., Sullivan, D. R., Mann, K., Simes, J., Best, J. D., Hamwood, S., & Keech, A. C. (2010) · Diabetologia · doi:10.1007/s00125-010-1806-9 · Cited by 94 · see citing works
Effectiveness of anthocyanin-containing foods and nutraceuticals in mitigating oxidative stress, inflammation, and cardiovascular health-related biomarkers: a systematic review of animal and human interventions
Mohammadi, N., Farrell, M., O'Sullivan, L., Langan, A., Franchin, M., Azevedo, L. C., & Granato, D. (2024) · Food & Function · doi:10.1039/d3fo04579j · Cited by 99 · see citing works
Plasma N -Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study
Wittenbecher, C., Štambuk, T., Kuxhaus, O., Rudman, N., Vučković, F., Štambuk, J., Schiborn, C., Rahelić, D., Dietrich, S., Gornik, O., et al. (2020) · Diabetes Care · doi:10.2337/dc19-1507 · Cited by 89 · see citing works
Update on the NCEP ATP-III emerging cardiometabolic risk factors
Eckel, R. H., & Cornier, M. (2014) · BMC Medicine · doi:10.1186/1741-7015-12-115 · Cited by 90 · see citing works
Obesity, weight loss and conditional cardiovascular risk factors
Tzotzas, T., Evangelou, P., & Kiortsis, D. N. (2010) · Obesity Reviews · doi:10.1111/j.1467-789x.2010.00807.x · Cited by 86 · see citing works
Emerging risk factors for cardiovascular diseases: Indian context
Gupta, S., Gudapati, R., Gaurav, K., & Bhise, M. (2013) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.117212 · Cited by 82 · see citing works
Apolipoprotein B: Bridging the Gap Between Evidence and Clinical Practice
Oliveira-Gomes, D. D., Joshi, P. H., Peterson, E. D., Rohatgi, A. K., Khera, A., & Návar, A. M. (2024) · Circulation · doi:10.1161/circulationaha.124.068885 · Cited by 80 · see citing works
Discordance analysis and the Gordian Knot of LDL and non-HDL cholesterol versus apoB
Sniderman, A. D., Lamarche, B., Contois, J. H., & Graaf, J. D. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000127 · Cited by 76 · see citing works
Self-citation
Apolipoproteins A1, B, and apoB/apoA1 ratio are associated with first ST-segment elevation myocardial infarction but not with recurrent events during long-term follow-up
Bodde, M. C., Hermans, M. P. J., Jukema, J. W., Schalij, M. J., Lijfering, W. M., Rosendaal, F. R., Romijn, F. P. H. T. M., Ruhaak, L. R., van der Laarse, A., & Cobbaert, C. M. (2018) · Clinical Research in Cardiology · doi:10.1007/s00392-018-1381-5 · Cited by 72 · see citing works
Evidence for changing lipid management strategy to focus on non-high density lipoprotein cholesterol
Su, X., Kong, Y., & Peng, D. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1080-x · Cited by 72 · see citing works
Impact of daily Chlorella consumption on serum lipid and carotenoid profiles in mildly hypercholesterolemic adults: a double-blinded, randomized, placebo-controlled study
Ryu, N. H., Lim, Y., Park, J. E., Kim, J., Kim, J. Y., Kwon, S. W., & Kwon, O. (2014) · Nutrition Journal · doi:10.1186/1475-2891-13-57 · Cited by 71 · see citing works
Non-HDL Cholesterol or apoB: Which to Prefer as a Target for the Prevention of Atherosclerotic Cardiovascular Disease?
Langlois, M. R., & Sniderman, A. D. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01323-z · Cited by 69 · see citing works
Exploiting the GTEx resources to decipher the mechanisms at GWAS lociPreprint
Barbeira, A., Bonazzola, R., Gamazon, E. R., Liang, Y., Park, Y., Kim-Hellmuth, S., Wang, G. T., Jiang, Z., Zhou, D., Hormozdiari, F., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/814350 · Cited by 70 · see citing works
Non–High-Density Lipoprotein Cholesterol, Guideline Targets, and Population Percentiles for Secondary Prevention in 1.3 Million Adults
Elshazly, M. B., Martin, S. S., Blaha, M. J., Joshi, P. H., Toth, P. P., McEvoy, J. W., Al-Hijji, M. A., Kulkarni, K. R., Kwiterovich, P. O., Blumenthal, R. S., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.045 · Cited by 68 · see citing works
Effects of endurance training on serum lipids
Fikenzer, K., Fikenzer, S., Laufs, U., & Werner, C. (2018) · Vascular Pharmacology · doi:10.1016/j.vph.2017.11.005 · Cited by 67 · see citing works
A Mediterranean-style, low–glycemic-load diet decreases atherogenic lipoproteins and reduces lipoprotein (a) and oxidized low-density lipoprotein in women with metabolic syndrome
Jones, J. L., Comperatore, M., Barona, J., Calle, M. C., Andersen, C. J., McIntosh, M. S., Najm, W. I., Lerman, R. H., & Fernández, M. L. (2011) · Metabolism · doi:10.1016/j.metabol.2011.07.013 · Cited by 66 · see citing works
Epidemiology and Primary Prevention of Stroke
Furie, K. L. (2020) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000831 · Cited by 70 · see citing works
Apolipoprotein B, non-HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk.
Holewijn, S., Den Heijer, M., Swinkels, D. W., H Stalenhoef, A. F., & De Graaf, J. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02277.x · Cited by 64 · see citing works
Plasma Proprotein Convertase Subtilisin/Kexin Type 9: A Marker of LDL Apolipoprotein B-100 Catabolism?
Chan, D. C., Lambert, G. C., Barrett, P. H. R., Rye, K., Ooi, E. M. M., & Watts, G. F. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2009.128645 · Cited by 62 · see citing works
Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets
Toth, P. P., Grabner, M., Punekar, R. S., Quimbo, R. A., Cziraky, M. J., & Jacobson, T. A. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.05.914 · Cited by 62 · see citing works
Using Apolipoprotein B to Manage Dyslipidemic Patients: Time for a Change?
Harper, C. R., & Jacobson, T. A. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0517 · Cited by 59 · see citing works
Niacin Therapy Increases High-Density Lipoprotein Particles and Total Cholesterol Efflux Capacity But Not ABCA1-Specific Cholesterol Efflux in Statin-Treated Subjects
Ronsein, G. E., Hutchins, P. M., Isquith, D. A., Vaisar, T., Zhao, X.-Q., & Heinecke, J. W. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306268 · Cited by 60 · see citing works
Impact of Novel Low-Density Lipoprotein-Cholesterol Assessment on the Utility of Secondary Non-High-Density Lipoprotein-C and Apolipoprotein B Targets in Selected Worldwide Dyslipidemia Guidelines
Sathiyakumar, V., Park, J., Quispe, R., Elshazly, M. B., Michos, E. D., Banach, M., Toth, P. P., Whelton, S. P., Blumenthal, R. S., Jones, S. R., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032463 · Cited by 58 · see citing works
Standardization of Apolipoprotein B, LDL‐Cholesterol, and Non‐HDL‐Cholesterol
Contois, J. H., Langlois, M. R., Cobbaert, C. M., & Sniderman, A. D. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.030405 · Cited by 57 · see citing works
Self-citation
Inflammation, Adiposity, and Atherogenic Dyslipidemia in Rheumatoid Arthritis: Is There a Paradoxical Relationship?
Bag‐Ozbek, A., & Giles, J. T. (2014) · Current Allergy and Asthma Reports · doi:10.1007/s11882-014-0497-6 · Cited by 57 · see citing works
Genetically Elevated LDL Associates with Lower Risk of Intracerebral Hemorrhage
Falcone, G. J., Kirsch, E. P., Acosta, J., Noche, R. B., Leasure, A. C., Marini, S., Chung, J., Selim, M. H., Meschia, J. F., Brown, D. L., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25740 · Cited by 57 · see citing works
Combination therapy of statins and fibrates in the management of cardiovascular risk
Fiévet, C., & Staels, B. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328332e9ef · Cited by 56 · see citing works
Lipoprotein Biomarkers and Risk of Cardiovascular Disease: A Laboratory Medicine Best Practices (LMBP) Systematic Review
Sandhu, P. K., Musaad, S. M. A., Remaley, A. T., Buehler, S. S., Strider, S., Derzon, J. H., Vesper, H. W., Ranne, A., Shaw, C. S., & Christenson, R. H. (2016) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2016.021006 · Cited by 55 · see citing works
Effect of PCSK9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy
Koren, M. J., Kereiakes, D. J., Pourfarzib, R., Winegar, D. A., Banerjee, P., Hamon, S., Hanotin, C., & McKenney, J. M. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.002224 · Cited by 52 · see citing works
Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk
Rosenson, R. S., Davidson, M. H., & Pourfarzib, R. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.03.038 · Cited by 51 · see citing works
Comparison of equations for the calculation of LDL-cholesterol in hospitalized patients
Martins, J., Olorunju, S. A. S., Murray, L., & Pillay, T. S. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.01.037 · Cited by 51 · see citing works
Update on the laboratory investigation of dyslipidemias
Ramasamy, I. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.01.015 · Cited by 50 · see citing works
Low-Density Lipoprotein Cholesterol, Apolipoprotein B, and Risk of Coronary Heart Disease
Imes, C. C., & Austin, M. A. (2012) · Biological Research For Nursing · doi:10.1177/1099800412436967 · Cited by 49 · see citing works
Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers
Brunell, S. C., Toth, P. P., Ramı́rez, G., Cobble, Chilton, & Chiquette (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s37969 · Cited by 49 · see citing works
Nutrigenetics of cholesterol metabolism: observational and dietary intervention studies in the postgenomic era
Abdullah, M. M. H., Jones, P. J. H., & Eck, P. K. (2015) · Nutrition Reviews · doi:10.1093/nutrit/nuv016 · Cited by 47 · see citing works
Cancer therapy's impact on lipid metabolism: Mechanisms and future avenues
Bhatnagar, R., Dixit, N. M., Yang, E. H., & Sallam, T. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.925816 · Cited by 47 · see citing works
Effects of Daily Intake of Calcium and Vitamin D-Enriched Milk in Healthy Postmenopausal Women: A Randomized, Controlled, Double-Blind Nutritional Study
Reyes‐García, R., Mendoza, N., Palacios, S., Salas, N., Quesada‐Charneco, M., García‐Martin, A., Fonollá, J., Lara‐Villoslada, F., & Muñoz‐Torres, M. (2018) · Journal of Women s Health · doi:10.1089/jwh.2017.6655 · Cited by 47 · see citing works
The clinical utility of apoB versus LDL-C/non-HDL-C
Kohli-Lynch, C. N., Thanassoulis, G., Moran, A. E., & Sniderman, A. D. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.05.001 · Cited by 47 · see citing works
Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study)
Ballantyne, C. M., Braeckman, R. A., Bays, H. E., Kastelein, J. J., Otvos, J. D., Stirtan, W. G., Doyle, R. T., Soni, P. N., & Juliano, R. A. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.11.009 · Cited by 46 · see citing works
Squalene monooxygenase – a target for hypercholesterolemic therapy
Belter, A., Skupińska, M., Giel-Pietraszuk, M., Grabarkiewicz, T., Rychlewski, L., & Barciszewski, J. (2011) · Biological Chemistry · doi:10.1515/bc.2011.195 · Cited by 46 · see citing works
The Present and Future of Lipid Testing in Cardiovascular Risk Assessment
Habeeb, N. W.-A., Higgins, V., Wolska, A. T., Delaney, S. R., Remaley, A. T., & Beriault, D. R. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvad012 · Cited by 45 · see citing works
Systematic Review: Evaluating the Effect of Lipid-Lowering Therapy on Lipoprotein and Lipid Values
Rosenson, R. S., & Underberg, J. A. (2013) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-013-6477-6 · Cited by 45 · see citing works
Cardiovascular Death in Dialysis Patients
Sniderman, A. D., Solhpour, A., Alam, A., Williams, K., & Sloand, J. A. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06300909 · Cited by 43 · see citing works
Oxidative stress and antioxidant levels in patients with anorexia nervosa: A systematic review and exploratory meta‐analysis
Solmi, M., Veronese, N., Manzato, E., Sergi, G., Favaro, A., Santonastaso, P., & Correll, C. U. (2015) · International Journal of Eating Disorders · doi:10.1002/eat.22443 · Cited by 40 · see citing works
Low-density lipoprotein and apolipoprotein B: Clinical use in patients with coronary heart disease
Cromwell, W. C., & Barringer, T. A. (2009) · Current Cardiology Reports · doi:10.1007/s11886-009-0067-z · Cited by 41 · see citing works
Update on Cardiovascular Disease Risk in Patients with Rheumatic Diseases
Mackey, R. H., Kuller, L. H., & Moreland, L. W. (2018) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2018.03.006 · Cited by 43 · see citing works
Both Serum Apolipoprotein B and the Apolipoprotein B/Apolipoprotein A-I Ratio Are Associated with Carotid Intima-Media Thickness
Huang, F., Yang, Z., Xu, B., Bi, Y., Xu, M., Xu, Y. H., Lu, J., Liu, Y., Dai, M., Zhou, W., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054628 · Cited by 40 · see citing works
Impaired ApoB-Lipoprotein and Triglyceride Metabolism in Obese Adolescents with Polycystic Ovary Syndrome.
Vine, D., Wang, Y., Jetha, M., Ball, G., & Proctor, S. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2854 · Cited by 40 · see citing works
Effects of orthodox religious fasting versus combined energy and time restricted eating on body weight, lipid concentrations and glycaemic profile
Karras, S. Ν., Koufakis, T., Adamidou, L., Antonopoulou, V., Karalazou, P., Thisiadou, K., Mitrofanova, E., Mulrooney, H. M., Petróczi, A., Zebekakis, P. E., et al. (2020) · International Journal of Food Sciences and Nutrition · doi:10.1080/09637486.2020.1760218 · Cited by 40 · see citing works
Associations of circulating choline and its related metabolites with cardiometabolic biomarkers: an international pooled analysis
Pan, X., Yang, J. J., Shu, X., Moore, S. C., Palmer, N. D., Guasch‐Ferré, M., Herrington, D. M., Harada, S., Eliassen, A. H., Wang, T. J., et al. (2021) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqab152 · Cited by 40 · see citing works
Comparability of lipoprotein particle number concentrations across ES-DMA, NMR, LC-MS/MS, immunonephelometry, and VAP: in search of a candidate reference measurement procedure for apoB and non-HDL-P standardization
Delatour, V., Clouet-Foraison, N., Gaie-Levrel, F., Marcovina, S. M., Hoofnagle, A. N., Kuklenyik, Z., Caulfield, M. P., Otvos, J. D., Krauss, R. M., Kulkarni, K. R., et al. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2018.288746 · Cited by 39 · see citing works
Self-citation
New insight into sortilin in controlling lipid metabolism and the risk of atherogenesis
Su, X., & Peng, D. (2019) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12561 · Cited by 39 · see citing works

Apolipoprotein B or Low-Density Lipoprotein Cholesterol: Is It Time for a Twenty-First-Century Lipid Marker?
Meeusen, J. W. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2018.286641 · Cited by 1 · see citing works
Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association
Soffer, D. E., Marston, N. A., Maki, K. C., Jacobson, T. A., Bittner, V. A., Peña, J. M., Thanassoulis, G., Martin, S. S., Kirkpatrick, C. F., Virani, S. S., et al. (2024) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2024.08.013 · Cited by 115 · see citing works
ApoB vs non-HDL-C vs LDL-C as Markers of Cardiovascular Disease
Sniderman, A. D. (2021) · Clinical Chemistry · doi:10.1093/clinchem/hvab140 · Cited by 28 · see citing works
Should apolipoprotein B replace LDL cholesterol as therapeutic targets are lowered?
Meeusen, J. W., Donato, L. J., & Jaffe, A. S. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000313 · Cited by 17 · see citing works
Is Apolipoprotein B and Small, Dense low density lipoprotein a better marker of cardiovascular risk?
Abiodun, I. S. (2015) · International Journal of Biomedical Research · doi:10.7439/ijbr.v6i10.2638

Authors: Contois, J. H., McConnell, J. P., Sethi, A. A., Csako, G., Devaraj, S., Hoefner, D. M., & Warnick, G. R.
Affiliations: Maine Standards Company, Windham, ME
Mayo Clinic (US)
National Institutes of Health (US)
National Institutes of Health, Bethesda, MD
University of California Davis Medical Center (US)
Marshfield Clinic (US)
Berkeley HeartLab Inc, Alameda, CA
Corresponding author: Contois, John H
ORCID: Contois, John H
Devaraj, Sridevi
Hoefner, Daniel M
Warnick, G Russell
Venue: Clinical Chemistry
Publisher: Oxford University Press (OUP)
Published: 2009-03-01
Volume: 55
Issue: 3
Pages: 407-419
ISSN: 0009-9147 (ISSN-L)
1530-8561
DOI: 10.1373/clinchem.2008.118356
OpenAlex: W2107424758
Cited by: 326
References: 97
Citations by year: 2026: 6 · 2025: 8 · 2024: 7 · 2023: 16 · 2022: 12 · 2021: 24 · 2020: 25 · 2019: 16 · 2018: 22 · 2017: 17 · 2016: 14 · 2015: 16 · 2014: 28 · 2013: 25 · 2012: 24
FWCI: 29.67
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
Locations: Clinical Chemistry (publishedVersion)
PubMed (publishedVersion)
Funders: NIH
Topics: Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
Keywords: apolipoprotein B, LDL particle number, LDL cholesterol, cardiovascular risk, lipid profile, Canadian guidelines, cardiovascular risk assessment
MeSH terms: Apolipoproteins B, Cardiovascular Diseases, Humans, Risk Factors, Clinical Chemistry Tests

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Apolipoprotein B and Cardiovascular Disease Risk: Position Statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks